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(Horatius, Carmina) 
CHAPTER 1 
INTRODUCTION 
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INTRODUCTION 
Short term growth studies as are reported in this 
thesis have become possible with the development of the 
ulnar length measuring technique by Valk (1-2) . The 
technical performance of the device as well as the metho-
dological approach of growth enable reliable detection 
of growth in ulnar length within time periods covering 
one third of the time needed with conventional body 
height measurements (3). The choice of the ulna as ob-
ject of this measuring technique was based on several 
grounds: one being the high correlation found earlier 
between body growth and growth in the length of the fore-
arm (4-5), another the fact that herewith endochondral 
growth of one long bone could be studied. The third 
reason was a practical one since adequate positioning 
of the forearm is relatively easy to perform and conve-
nient to both patient and observer. 
As to the technical aspects there are two important 
issues to be mentioned here. First the fact that this 
technique is not invasive which makes it applicable as 
frequently as wanted, even several times a day as is il-
lustrated in chapter one. This in contrast to earlier 
reported conventional X-ray studies (6-9) and the recently 
developed Roentgen stereophotogrammetric method (8) which 
was used by Aronson for growth studies (9). This latter 
technique is even more invasive since it necessitates the 
implant of metalic markers and the use of X-rays for each 
length determination. The second important issue of the 
ulnar length measuring technique is the attainment of 
maximal reproducibility of the position of the forearm 
by a fixing apparatus (1). Lack of reproducibility of 
the position chosen is one of the very errors in body 
height measurements. Reproducibility in this determi-
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nation can only be achieved by quickly repeated body 
height measurements since, as Lewin demonstrated (10-11), 
the extent of the measurement error is time dependent: 
the longer the time interval between the measurements 
the higher the error. This time dependent effect on the 
error of measurement is eliminated in the ulnar length 
measuring technique since the fixing apparatus ensures a 
precisely reproducible position of the forearm over short 
as well long time periods. 
The most important methodological issue is the choice 
of determining the change in ulnar length i.e. the growth 
rate rather than the absolute ulnar length, since only 
this provides a direct insight in actual growth activity. 
This is expressed by using the Three week Ulnar Growth 
rate i.e. TUG-rate (mm) as outcome of the determination. 
Especially in response studies as described in the follo-
wing chapters the increment method is to prefer above ab-
solute lengths, because the effect of the therapy on 
growth velocity is directly illustrated. But also longer 
term evaluation of intra- and interindividual growth ac-
tivity in the adolescent growth spurt is reflected bet-
ter by the growth rate since Tanner stated: "....the 
amount of height added during the spurt is to a consi-
derable degree independent of the amount attained before" 
(12). This was confirmed for growth in ulnar length. The 
correlation between ulnar length attained before puberty 
and length added during the spurt was very poor, ranging 
from r = 0.06 to r = 0.11 (13). 
Another essential methodological aspect is that each 
determination comprises six successive independent mea-
surements. This provides a mode to calculate a limit of 
confidence enabling instant statistical testing of each 
separate TUG-rate, which is essential for evaluation of 
short term growth in individual subjects. The mean stan-
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dard error (SE) of the samples in the studies reported 
here amounts to 0.09 mm from which a mean limit of confi­
dence of 0.18 mm (1.96 χ SE) can be derived. 
The study on ulnar growth in boys around the age of 
puberty (3) resulted in mean values for normal prepuber­
tal and pubertal ulnar growth rates, being 0.60 and 
1.00 mm per three weeks respectively. Furthermore it was 
demonstrated that growth in body height is approximately 
five times higher than growth in ulnar length, the corre­
lation between the two being as high as 0.83. Unpublished 
data on normal girls reveal virtually the same mean pre­
pubertal and pubertal TUG-rates as in boys. These growth 
rates are used as reference for evaluation of growth rates 
in children with growth disorders. 
Before introducing the following chapters separately 
a few general remarks on the patients studied have to be 
made. All patients were screened thoroughly in order to 
exclude endocrine disorders. So patients participating 
in these studies in fact show a variant of normal growth 
(14-16). They can be grossly divided into two groups: 
those who are 2 standard deviations (SD) or more below 
and those who are 2 SD or more above the 50th centile 
for body height in normal Dutch children (17). The patients 
below the 10th centile were all boys with constitutional 
delay in growth and sexual development. The patients above 
the 97th centile were both girls and boys with tall stature. 
Treatment was only started in the subjects with serious 
psychological problems because of their outstanding posi­
tion amongst their peers. The number of adolescents seeking 
help for these problems due to either short or tall sta­
ture is estimated to be about 25%o (18-19) , which is 
much higher than the number of adolescent patients with 
endocrine disorders as the cause of excessively tall or 
short stature. 
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However, before patients treated for growth disorders 
could be studied one problem had to be solved, i.e. the 
phenomenon of transitional changes in ulnar length during 
the day (3). This was important since the extent of these 
transitional changes might influence evaluation of growth 
rates on the very short term. In the second chapter the 
results are described of a study on the intradaily vari­
ation of the ulnar length in eleven normal boys. Since 
the study period covered a time interval of three weeks, 
growth in ulnar length was also studied. The outcome of 
this study appeared to be of utmost importance in evalua­
ting the effects of drug administration in subjects with 
growth disorders. 
The next chapter reports on the growth promoting ef­
fect of diagnostic use of human chorionic gonadotropin 
(hGC) in a group of boys with delay in growth and sexual 
development. The dose hCG given was 1 χ 1500 IU on three 
consecutive days for assessment of the androgenic res­
ponsiveness of the Leydig cell. The growth promoting 
effect of hCG is known since 1940 (20), but was never 
studied before on this short term after such low dose. 
Chapter four compares two therapeutic hCG regimens 
in two groups of boys with delayed puberty. In view of 
the reported temporal irresponsiveness of the Leydig 
cell to successive hCG injections (21-23) and the 
results described in chapter two it was thought worth­
while to compare the responses in growth rates after 
a weekly single dose of hCG (1 χ 1500 IU) and the 
usually recommended weekly multiple hCG regimen (3 χ 1500 
IU) (24-26). 
The following two chapters deal with estrogen therapy 
in tall girls and tall boys. Rather high dose estrogen 
therapy in tall girls is in focus and ample reports have 
appeared in literature. In chapter five the effect of 
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low dose of estrogen on growth in tall girls is studied. 
The aim of the study was to demonstrate that even a low 
dose of estrogens decelerates growth velocity and does 
so instantly. 
Chapter six for the first time reports on the results 
of a similar low dose estrogen administration in tall boys. 
Especially in these boys instant growth inhibition is 
often of great importance. The usually recommended an­
drogen therapy, however, exerts growth promotion in the 
initial phase of therapy (27-28). The study was started 
in view of recent data on the mode of action by which 
estrogens effectuate an instant growth inhibition by 
lowering plasma somatomedin levels (19,29). 
Except for the effect on growth velocity per se, con­
comitant changes in growth related biochemical parameters 
were also studied in order to correlate them with the 
changes in TUG-rates. 
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CHAPTER 2 
INTRADAILY VARIATION OF THE HUMAN ULNAR 
LENGTH AND SHORT TERM GROWTH - A 
LONGITUDINAL STUDY IN ELEVEN BOYS 
I.M. VALK 
J.S.G. VAN DEN BOSCH 
18 
SUMMARY 
In order to detect the intradaily variation of the 
clinical ulnar length in eleven boys the right ulnar 
length was determined using a condylograph at seven set 
times of each day during a study period of three weeks. 
The mean standard error of the determinations amoun­
ted 0.0 9 mm. In 86% of the days concerned the ulnar 
length changed significantly (one way analysis of vari­
ance, ρ <0.05). As far as the whole group was concerned 
the ulnar length decreased significantly during the time 
interval from 8.00 h to 12.00 h (Friedman's related sam­
ples test, ρ <0.01). The decrement amounted 0.4 mm. 
During the rest of the day the changes in the ulnar length 
were not significant. A consistent decrement of the ulnar 
length during the day in combination with total growth of 
0.99 mm during the three week study period suggested that 
growth in length of the human ulna occurs during the 
night. 
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INTRODUCTION 
The human ulnar length can be determined relatively 
accurately using a condylograph (1-2). The major problem 
in this determination is the dynamics of the soft tissues 
inclusive of the epiphyseal discs (3). The transient 
changes in the ulnar length as mentioned in an earlier 
publication (4) are the consequences of the dynamics of 
the soft tissues. Unpublished results of measurements 
of the ulnar length in the same individuals at different 
moments of the day suggested that the transient changes 
in the ulnar length might follow a pattern during the 
day. It was thought worthwhile to investigate the intra-
daily variation in the ulnar length. 
In our laboratory short term ulnar growth is mostly 
investigated over time intervals of three weeks (1-2,4). 
Therefore we were interested in the intradaily variation 
of the ulnar length over that period. This time interval 
enabled the investigation of the total growth in length 
of the ulna during the whole study period. 
MATERIALS AND METHODS 
Eleven boys of a boarding school participated in this 
study. In order to follow the changes in the ulnar length 
during the day, their right ulnar length was determined 
as often as possible at seven chosen set times, during a 
study period of three weeks, at all days of the week ex-
cept for the weekends. The mean age of the group studied 
was 11.54 years (ranging from 9.5 to 12.5 years). The 
ulnar length was measured using the ulnar measuring tech-
nique described earlier (1-2). Each determination com-
prised six successive independent measurements. All the 
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measurements were performed by one and the same observer. 
The standard deviation of the error of measurement 
was 0.22 mm. A mean standard error of the samples amoun­
ting 0.09 mm can be derived. 
The occurrence of significant changes in ulnar length 
during the day was tested for each subject, and each day 
separately using the one way analysis of variance. 
Whether differences between the ulnar length at the 
seven time moments of the day were significant for the 
whole group was tested using Friedman's related samples 
test. In order to detect the time intervals during which 
the ulnar length changed significantly, the signed rank 
test for paired observations was used. 
The total ulnar growth during the whole study period 
was assessed for each single individual by subtracting 
the mean ulnar length of the last day of the study period 
from the mean ulnar length of the first day. The signifi­
cance of the changes in the ulnar lengths was tested using 
the Student's T-test. 
RESULTS 
In table 1 the mean ulnar lengths at seven moments of 
the day are tabulated for each individual separately. It 
is to be remembered that these means are calculated from 
the results of the measurements at the corresponding time 
moments of all the days concerned. Due to social interfer­
ence, the intended number of 176 days of investigation -
16 days of investigation on 11 boys - was not reached. 
The actual number of days of investigation amounted 134. 
In 86% (115) of the days of investigation (134) the ulnar 
length changed significantly within the time interval 
from 8.00 h to 18.00 h (one way analysis of variance, ρ < 0 .05) . 
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In f igure 1 the mean ulnar lengths a t seven moments 
of the day are i l l u s t r a t e d for the whole group. 
Table 1 and f igure 1 reveal t h a t as far as the whole 
group i s concerned the length of the ulna i s longest ear­
ly in the morning and s h o r t e s t a t noon. For the whole 
group s tudied the means of the ulnar lengths d i f fe r s ig­
n i f i c a n t l y during the day (Friedman's r e l a t e d samples 
t e s t , ρ < 0 . 0 1 ) . During the time i n t e r v a l from 8.00 h t i l l 
12.00 h the ulnar length decreases 0.4 mm (signed rank 
t e s t , ρ <0 .05) . During the time i n t e r v a l from 12.00 h 
t i l l 13.0 0 h the u lnar length increases 0.12 mm. From 
13.00 h t i l l 17.00 h the ulnar length increases 0.06 mm. 
From 17.00 h t i l l 18.00 h there i s a decrement amounting 
0.06 mm. The changes a f t e r 12.00 h are not s i g n i f i c a n t 
(signed rank t e s t , ρ >0.05) . 
In tab le 2 the mean ulnar length a t the f i r s t day and 
a t the l a s t day of the study period are compiled for each 
Sub]. 
no. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
08.00 
226.66 
215.94 
219.08 
224.19 
249.93 
256.57 
219.77 
243.77 
235.20 
241.82 
229.82 
10.00 
226.80 
215.84 
219.03 
223.98 
249.70 
256.44 
219.34 
243.64 
234.83 
241.15 
229.62 
Moments 
12.00 
226.77 
216.12 
218.35 
223.84 
248.95 
256.41 
219.91 
243.25 
233.92 
241.53 
229.32 
of the day (hr) 
13.00 
226.58 
215.59 
218.93 
223.79 
249.74 
256.39 
219.60 
243.24 
234.85 
241.59 
229.45 
16.00 
226.53 
215.84 
218.96 
223.82 
249.71 
256.44 
219.59 
243.40 
235.12 
241.41 
229.43 
17.00 
226.75 
215.79 
219.06 
223.77 
249.88 
256.30 
219.66 
243.32 
234.99 
241.32 
229.58 
18.00 
226.58 
215.69 
219.84 
223.74 
249.49 
256.44 
219.70 
243.30 
235.03 
241.60 
229.45 
TABLE 1. The means of the mean u l n a r lengths a t seven moments of 
t h e day of a t h r e e week study per iod in eleven boys of a boarding-
school , expressed in mm. 
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individual separately. The difference between the mean 
ulnar length of the first day and the last day of the 
study period appeared to be significant in all subjects 
concerned (Student's T-test, p<0.01). From table 2, ex-
cluding the results of the subjects 7 and 10, a mean 
three week ulnar growth rate of 0.99 mm can be calculated. 
Mean ulnar length 
( mm) 
233 00 
232 90 
232 50 
800 1000 12 00 13 00 1600 1700 1800 
Moments of the day 
FIG. 1. The mean u lna r length a t seven moments of the day in e l e -
ven boys. 
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Subj . 
no. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
mean ulnar length in mm 
date: 13 01 75 
225.55 
215.13 
218.13 
223.40 
218.91 
256.08 
219.47 
242.94 
233.97 
241.14 
229.12 
date: 03 02 75 
226.63 
216.37 
219.11 
223.92 
220.43 
256.76 
219.86* 
243.63 
235.41 
241.73** 
229.66 
*date: 23 01 75; **date 22 01 75 
TABLE 2. The mean ulnar length of the first and the last day of 
a three week study period in eleven boys. 
DISCUSSION 
In the group of eleven boys studied the intradaily 
changes of the clinical ulnar length follow a pattern. 
The ulnar length decreases significantly during the morn-
ing, 0.4 mm during the time interval of four hours. 
The occurrence of intradaily rhythms in the ulnar 
length must be taken into account whenever short term 
ulnar growth studies are made with the measuring tech-
nique used. The results of this short term longitudinal 
study revealed a mean total ulnar growth of 0.99 mm 
during the whole three week study period. This finding 
is in accordance with the three week ulnar growth rate 
in boys around the age of puberty as earlier reported (4). 
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The facts: i a consistent decrement of the ulnar 
length during the day, ii the insignificant changes from 
noon to 18.00 h and iii the total growth during the three 
week study period suggest that growth in length of the 
human ulna occurs during the night. 
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CHAPTER 3 
SHORT TERM GROWTH IN BOYS WITH DELAYED 
PUBERTY AFTER DIAGNOSTIC HUMAN 
CHORIONIC GONADOTROPIN ADMINISTRATION 
J.S.G. VAN DEN BOSCH 
A.G.H. SMALS 
P.W.C. KLOPPENBORG 
I.M. VALK 
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SUMMARY 
Using a sensitive measuring device, three-day hCG 
administration (Pregnyl; 1500 IU daily) was shown to 
temporarily increase ulnar growth velocity from prepu-
bertal (0.40 ± 0.35 nun/three weeks) to pubertal values 
(1.1 ± 0.6 4 mm/three weeks) in ten boys with delayed 
puberty. 
The growth-promoting effect of diagnostic hCG ad-
ministration, which was demonstrable for three to nine 
weeks, was associated with an overt rise in plasma tes-
tosterone from 129 ± 126 to 818 ± 419 ng/100 ml and an 
approximate doubling of the serum alkaline phosphatase 
activities from 193 ± 46 to 376 ± 115 U/liter, sugges-
ting an initiated growth spurt. 
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INTRODUCTION 
The Leydig cell responses to short term hCG adminis­
tration are well documented in literature (1-5) . Since 
Dorff (6) in 1940 reported on the beneficial effects of 
long term administration of hCG on growth and develop­
ment in patients with constitutional growth retardation, 
ample reports have appeared in literature on the growth-
promoting effect of either endogenous or exogenous tes­
tosterone administration (6-8) 
To our knowledge, however, the effect of diagnostic 
hCG administration on short term growth has never been 
described. Since the development of a sensitive measur­
ing device by Valk (9-10) enables accurate measurement 
of the ulnar length (9-12), it was thought worthwhile 
to study the effect of a three-day hCG stimulation test 
in boys with delayed puberty. 
MATERIALS AND METHODS 
Ten boys with constitutionally delayed puberty parti­
cipated in this study. The mean age (± SD) was 15.1 ± 1.1 
yr, whereas the skeletal age, according to Greulich and 
Pyle (13), was 11.4 ± 0.7 yr. Body height amounted to 
150.6 ± 9.1 cm and was below the 10th percentile for Dutch 
children (14) in nine of the ten boys. Body weight was 
42.7 ± 12.6 kg and was below the 10th percentile for seven 
out of 10 boys. All boys were in Tanner stage I-II. 
During a clinical stay of one to two weeks for endo­
crinological evaluation of their growth retardation, 1500 
ρ 
IU hCG (Pregnyl ) were given im during three consecutive 
days for diagnostic purposes. Blood for testosterone and 
alkaline phosphatase measurements was sampled before and 
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after hCG administration. Measurements of ulnar length 
and body height were performed in all boys during three 
consecutive periods: 1) the period preceding the hCG loa­
ding (mean duration 9.2 ± 5.0 weeks; range 3-18 weeks), 
2) the early follow-up period immediately after hCG ad­
ministration (mean duration 5.0 ± 2.3 weeks; range 3-9 
weeks), and 3) the second follow-up period (mean duration 
6.1 ± 2.2 weeks; range 3-9 weeks). During this period, 
one of the boys could not participate due to the start of 
therapeutic administration of hCG. 
For several reasons it was not possible to choose 
identical time intervals for each separate study period and, 
unfortunately, there were no data available on alkaline 
phosphatase activities during the second follow-up period. 
The ulnar length was measured using a sensitive 
measuring device, developed and described by Valk (9-10), 
consisting of a fixing apparatus, a condylograph, and a 
measuring block. The fixing apparatus immobilizes the 
forearm in a reproducible manner in the position shown in 
figure 1A. The condylograph, shown in the same figure, 
consists of a metal cylinder fixed in a metal block allow­
ing rotation around its longitudinal axis. The block is 
set in a metal frame with a spring enabling the observer 
to draw the cylinder under a reproducible pressure along 
the ulnar side of the right hand till the condylograph 
reaches the measuring point located between the styloid 
process of the ulna and the os triquetrum (figure 1A). 
When the measuring point is found, a resilient awl, 
placed in the center of the cylinder, can be moved 
downward to contact the measuring block (figure 1, Bl 
and C). This block (figure 1С) is composed of 100 metal 
plates of 0.1 mm tickness isolated from each other by 
0.083 mm thin layers of a plastic. Each plate is connec­
ted to its own lamp, thus indicating a distance of 0.183 
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FIG. 1. The essentials of the ulnar length measuring technique. 
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mm to the next lamp. The lamps are collected in an an-
nunciator in order to read out the results easily (fig-
ure IB). Since the measuring range of the block itself 
is limited (1.83 cm), it can be moved in a slide and 
fixed in bores at intervals of 10,000 mm exactly enabling 
adaptation of the block to the length of the individual 
forearm. So changes in ulnar length can be expressed in 
lamps, and by multiplying with 0.183, in millimeters. The 
absolute ulnar length (figure 1B2) is determined by 
adding the calculated millimeters to the scaled distance 
between the block and the point of reference. Each ulnar 
length determination comprises six successive independent 
measurements, with a mean SE of 0.09 mm (the mean ulnar 
length at the start of the study was 238.58 ± 20.57 mm). 
Reliable detection of growth requires a change in ulnar 
length above approximately 0.2 mm. A period of three 
weeks has proved to be long enough to detect growth, since 
normal values for prepubertal and pubertal growth velocity 
amount to about 0.6 and 1.0 mm respectively. Growth in 
ulnar length was expressed 1) as the Three week Ulnar 
Growth rate (TUG-rate), calculated as shown in figure ID 
and 2) as the increase in absolute ulnar length in milli-
meters. Growth in body height was measured using a stan-
dard device and was expressed as the three week body 
growth rate in centimeters. Growth in ulnar length has 
been demonstrated, at least over the long term, to corre-
late highly with growth in body height (11). 
Plasma testosterone levels were measured using an anti-
serum generated in rabbits against 11-hydroxytestosterone 
hemisuccinate conjugated to albumin (15). Normal values 
for adult men are 314-1342 ng/100 ml. Serum alkaline phos-
phatase was measured using the Bessy and Lowry technique 
(16) adapted to automated analysis. 
Unless otherwise stated, the mean values are given ± 1 SD. 
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STATISTICAL ANALYSIS 
Differences in ulnar growth velocities during the res-
pective periods were evaluated in two ways. 
1) In case two successive periods were compared a 
direct graphical method was used to deal with the variable 
observation times. The three ulnar measurements (Ui, U2 
and Ua) were plotted against time. Ui is the measurement 
at the beginning of the first period. U2 is the one at the 
end of the first and the beginning of the second period, 
and Ua is the measurement at the end of the second period. 
Ui and U3 are connected by a straight line indicating the 
average growth velocity during the total time period. The 
position of U2 relative to this line is a measure for 
differences in growth velocity. If U2 is above this line, 
the average growth velocity during the first period is 
larger than the velocity during the second period. Uj 
below this line implies a larger velocity during the 
second period. A statistical test for differences in 
growth velocities between the two time periods includes 
Student's one-sample test for the whole group on the ver-
tical distances between U2 and the line U1-U3. This 
technique was used to test the differences in average 
growth velocities between time periods 1 and 2 and be-
tween time periods 2 and 3. To quantify these differ-
ences, the respective mean TUG-rates were used and tested 
by Student's T-test for paired observations. 
2) To compare the differences in growth velocities 
during the two separate time periods the difference be-
tween the mean TUG-rates of the pretreatment period and 
the second follow-up was tested for the whole group using 
Student's test for paired observations. 
Differences in plasma testosterone, serum alkaline 
phosphatase levels, and three week growth velocities in 
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body height during the different time periods of the 
study were also tested using Student's test for paired 
observations. 
RESULTS 
In figure 2 the changes in mean and individual TUG-
rates, plasma testosterone levels, and serum alkaline 
phosphatase activities are depicted. Using the direct 
graphical method, a significant change in average growth 
velocity was assessed between the period before hCG loa­
ding and the early follow-up (p<0.01) and between the 
early and the second follow-up period {p<0.05). The mean 
TUG-rate increased from 0.40 ± 0.35 mm before hCG loading 
to 1.1 ± 0.64 mm during the early follow-up period 
(p<0.05), whereas the mean TUG-rate decreased to 0.65 ± 
0.28 mm during the second follow-up period (p<0.05). The 
difference between the mean TUG-rates during the pre­
treatment period and during the second follow-up period 
lacked statistical significance (0.05 <ρ<0 .10) . 
No statistically significant differences were found 
between the three week growth velocities in body height 
during the respective periods (0.2 ± 0.2 cm before hCG 
loading, 0.2 ± 0.2 cm during the early follow-up period, 
and 0.4 ± 0.2 cm during the second follow-up (p>0.10). 
The mean plasma testosterone level increased from a 
basal level of 129 + 126 to 818 + 419 ng/100 ml immedi­
ately after hCG loading (p<0.01). The mean plasma tes­
tosterone level during the second follow-up amounted to 
213 ± 122 ng/100 ml and was not significantly different 
from the mean pretreatment value (p>0.10). The mean 
serum alkaline phosphatase activity increased from 193 
± 46 U/liter in the period before hCG loading to 376 ± 
115 U/liter during the early follow-up period (p<0.05). 
ALKALINE PHOSPHATASE (U/l) THREE WEEK ULNAR GROWTH RATE (mm) 
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DISCUSSION 
Using a sensitive measuring device, hCG administration 
for three days was shown to increase ulnar growth velocity 
in boys with delayed puberty to a level of pubertal growth 
spurt (1.0 mm/three weeks), as described by Valk for nor-
mal Dutch boys (11) . During the second follow-up, this 
growth promoting effect faded, reaching a prepubertal va-
lue of about 0.6 mm/three weeks as previously reported by 
this laboratory (9-11). This temporary growth accelerating 
effect of hCG was not detected by conventional body height 
measurements due to the high measurement error relative to 
the growth in body height during this short term growth 
study. The growth enhancement was accompanied by a huge 
increase in plasma testosterone levels and an almost doub-
ling of the serum alkaline phosphatase activities in the 
early follow-up period. 
To our knowledge, no data are available on the effect 
of hCG, administered on three consecutive days only, on 
growth and serum alkaline phosphatase activity. In a few 
other studies, a transient effect of hCG on growth veloci-
ty and serum alkaline phosphatase activity was assessed 
only after long term treatment (7-8). 
The growth promoting effect of hCG administration is 
probably mediated by its androgen stimulating effect (17-
22). Althought the precise mechanism is unknown, the pre-
sent study illustrates that, by use of the not invasive 
ulnar length measuring technique, a growth promoting ef-
fect of diagnostic hCG administration can be detected in 
boys with delayed puberty closely coinciding with an 
early rise in plasma testosterone levels and serum alka-
line phosphatase activities. 
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CHAPTER 4 
LACK OF DIFFERENCE IN GROWTH STIMULATING 
EFFECT BETWEEN WEEKLY SINGLE AND MULTIPLE 
HUMAN CHORIONIC GONADOTROPIN ADMINISTRATION 
IN BOYS WITH DELAYED PUBERTY 
J.S.G. VAN DEN BOSCH 
A.G.H. SMALS 
I.M. VALK 
P.W.C. KLOPPENBORG 
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SUMMARY 
Using a non-invasive sensitive ulnar length measuring 
technique short term growth was studied in two groups of 
boys with constitutional delay in growth. In one group (A) 
a protocol of multiple hCG injections weekly was used 
(3 χ 1500 IU), whereas the other (Group B) received a 
single dose of hCG weekly (1 χ 1500 IU), both during six 
weeks. 
The two hCG protocols appeared to be equally potent 
in stimulating Three week Ulnar Growth rates (TUG-rates), 
tripling the growth velocities from prepubertal to puber­
tal levels. 
After stopping hCG treatment the mean TUG-rate de­
creased again to a post-treatment level that, taking both 
groups together, was significantly higher than the mean 
pretreatment TUG-rate. 
During hCG administration mean body growth rates also 
rose significantly in the two groups. The extent of the 
changes, however, only allowed evaluation for the whole 
group in contrast to the changes in TUG-rates which far 
exceeded the limits of confidence in all but one boy. 
Serum alkaline phosphatase activities (APA) increased 
significantly during hCG treatment and almost parallelled 
the increase in TUG-rates. The APA response (ΔΑΡΑ) in 
Group A, however, was unexpectedly higher than in Group B. 
After stopping hCG treatment the mean APA significantly 
decreased taking both groups together to an almost pre­
treatment level. 
The data found indicate that a weekly single dose hCG 
regimen was sufficient and as effective as the weekly mul­
tiple injection protocol to stimulate TUG-rates to pubertal 
levels in the group of constitutionally delayed boys studied. 
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INTRODUCTION 
Sex hormone treatment of constitutionally short stature 
in boys with delayed puberty has been discussed since Dorff 
in 1935 discovered the growth promoting effect of human 
chorionic gonadotropin (hCG) (1-5). Accelerated onset of 
growth spurt during androgen therapy was found indeed but 
also a possible reduction in final body height due to 
accelerated closure of the epiphyseal discs (6-7) . However, 
Reiss et al. (2) and Kaplan et al. (4), treating consti-
tutionally short boys with hCG and testosterone respective-
ly, did not find evidence for premature epiphyseal closure, 
confirming earlier reports (8-9). Kaplan even suggested 
that the group treated reached a final height closer to the 
predicted height than the control group. Nevertheless, the 
risk of reduced final body height by androgen therapy in 
boys with delay in growth is still emphasized in literature. 
This added to reported adverse effects, led to reserve in 
hormonal treatment so that stimulation of growth is now 
only recommended in those cases where serious psychological 
problems arise (10-13). 
However, in case therapy is necessary, there is no con-
sensus about the kind of androgen stimulation - exogenous 
or endogenous -, the lowest effective dose and the way of 
administration to achieve the best results with lowest ad-
verse effects. As to gonadotropins as growth promoting 
agent, recent research demonstrated that even diagnostic 
use hCG (1500 IU daily for three days) caused growth acce-
leration to pubertal levels for as long as six weeks (5). 
Furthermore Smais et al. (14) demonstrated that there was 
no significant difference in Leydig cell responsiveness 
after single or daily repeated hCG administration, due to 
relative refractoriness to subsequent gonadotropin adminis-
tration for at least 48 hr after the priming dose (15-16). 
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Moreover, it has also been documented that one single dose 
of hCG may increase testosterone levels in boys with de­
layed puberty as long as 144 hr or even longer (14, 17-18). 
These data led us to compare the growth promoting ef­
fect of the generally recommended protocol of weekly mul­
tiple hCG injections (19-22) and a weekly single dose hCG 
regimen in two groups of boys with constitutional delay in 
growth using the ulnar length measuring technique (5, 23-24). 
MATERIALS AND METHODS 
Two groups of boys with constitutional delay in 
growth participated in this study after obtaining informed 
parental consent. Eight boys were treated with 3 χ 1500 IU 
hCG (Pregnyl ) weekly im for six weeks (Group A) and nine 
boys with 1 χ 1500 IU hCG weekly im for the same period 
(Group B). 
Data on growth and development of both groups at the 
start of the study are tabulated in table 1. In all boys 
body height was below the 10th centile for Dutch boys (25). 
Mean bone age according to Greulich and Pyle (26) was re­
tarded for an average of four years in the two groups. 
Although Group В contained boys younger, smaller and 
lighter the differences with Group A were not significant 
(p > 0.10) . 
The study was divided into three parts: before, during 
and after hCG administration each covering a time interval 
of six weeks. After assessing the growth promoting effect 
of hCG for each group separately the difference in response 
to weekly multiple (Group A) and single (Group B) hCG ad­
ministration was evaluated. The effect of stopping the 
gonadotropin administration could be assessed in six boys 
of each group. 
GROUP 
A 
3x1500 IU 
hCG/weekly 
В 
1x1500 IU 
hCG/weekly 
η 
θ 
9 
mean 
range 
mean 
range 
AGE 
(yr) 
16.2 + 0.8 
15.0 - 17.0 
15.6 + 0.9 
14.5 - 17.0 
BONE AGE 
(yr) 
12.0 + 1.0 
11.0 - 14.0 
11.6 ± 1.4 
10.0 - 14.0 
BODY HEIGHT 
(cm) 
153.0 + 9.7 
135.3 - 166.4 
148.0 + 6.5 
138.0 - 159.7 
BODY WEIGHT 
(kg) 
44.9 ± 9.0 
35.0 - 58.2 
40.2 -t 7.5 
29.8- 51.4 
TANNER 
STAGE* 
Gl-2 
Pl-2 
Gl-2 
Pl-2 
TESTOSTERONE 
(ng/100 ml) 
56 ± 29 
24 - 107 
56 ± 48 
23- 126 
* G = genital stage 
Ρ = pubic hair stage 
•^  TABLE 1. Characteristics on growth and development in two groups of boys with short stature and 
delayed puberty treated with two different hCG regimens for six weeks. No statistically significant 
differences in basic characteristics were found between the two groups. 
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Growth velocities were measured using the ulnar length 
measuring technique developed and described by Valk (23-24) 
and recently by van den Bosch et al (5). This technique 
enables accurate measurement of short term growth (5, 27-
28). Each ulnar length determination comprises six succes-
sive independent measurements by the same observer. The 
mean of the SD of the samples in this study amounted to 
0.20 mm implying a SE of 0.08 mm. Growth in ulnar length 
was expressed as the Three week Ulnar Growth rate in mm, 
i.e. TUG-rate, which actually reflects the change in ulnar 
length per three weeks. 
Growth in body height was determined using the Harpen-
den stadiometer and expressed as the three week body 
growth rate in cm. 
Blood for measurement of serum alkaline phosphatase 
activities was sampled before, during and after hCG 
loading. Serum alkaline phosphatase activities were mea-
sured using the Bessy and Lowry technique (29), adapted 
to automated analysis. Blood for measuring testosterone 
levels was sampled before and after hCG loading. Plasma 
testosterone was assayed after a paper chromatographic 
purification step using an anti-serum generated in 
rabbits against 11-hydroxytestosterone hemisuccinate 
conjugated to albumin (30) . Unfortunately, blood for 
testosterone was sampled at different time intervals 
after the last injections in the two groups. Therefore 
these data did not allow appropriate comparison of 
actual Leydig cell stimulation and were excluded from 
the present study. 
Mean values are given + 1 SD. 
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STATISTICAL ANALYSIS 
Statistical analysis was performed using Student's 
T-test for paired (P values are denoted by p) and unpaired 
data (P values are denoted as p*). The chosen level of 
statistical significance (two-sided) was ρ = 0.05. 
RESULTS 
the growth promoting effect of hCG administration (fig. 1) 
In the two groups studied hCG administration caused 
a significant increase in ulnar growth velocity. The mean 
TUG-rates tripled, in Group A from a pretreatment value 
of 0.46 ± 0.30 mm to 1.37 ± 0.31 mm during hCG loading 
(p< 0.001) and in Group В from 0.35 ± 0.28 mm to 1.07 ± 
0.34 mm (p< 0.005). In all boys of Group A and in eight 
out of nine boys of Group В the increase in TUG-rate 
during hCG treatment far exceeded the limit of confidence 
(3 χ SE). 
Mean body growth rates also increased significantly in 
the two groups, from 0.2 ± 0.1 cm before to 0.6 ± 0.3 cm 
during hCG administration in Group A (p<0.01) and from 
0.3 t 0.2 cm to 0.6 ± 0.1 cm in Group Β (ρ < 0.005) . 
comparison of the growth promoting effect of weekly single 
and multiple hCG administration (fig. 1) 
There was no difference in mean pretreatment TUG-rates 
between the two groups (p* >0.10) and although there was a 
tendency for a higher mean TUG-rate in Group A during hCG 
administration as compared to Group B, the difference also 
lacked statistical significance (0 .10 >p*>0.05). 
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The mean increase in TUG-rate (Δ TUG-rate) during 
hCG loading in Group A (0.91 ± 0.35 mm) was not signi­
ficantly different from the Δ TUG-rate in Group В (0.72 
± 0.52 mm) (p* > 0.10) . 
The same lack of statistical significance was found 
for the differences in absolute body growth rates before 
and during hCG administration as well as for the difference 
in the increase in the mean body growth rates (Δ body growth 
rate) between both groups (0.4 ± 0.3 cm for Group A and 0.3 
± 0.2 cm for Group B) (p*>0.10). 
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FIG. 1. The changes in mean (0---0) and individual (· ·) Three 
week Ulnar Growth rates (TUG-rates) during six weeks of a weekly 
multiple (A) and single dose hCG regimen (B) in boys with delayed 
puberty. The numbers refer to the individual patients. 
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the effect of stopping hCG injections (fig.2) 
After stopping drug therapy the mean TUG-rates de­
creased to almost equal levels: in Group A from 1.45 ± 
0.27 to 0.76 ± 0.21 mm (p <0.005) and in Group В from 
1.07 ± 0.40 to 0.75 ± 0.45 mm (p<0.10). 
The mean pretreatment TUG-rate in Group A (0.58 ± 
0.19 mm) was significantly lower than the mean post-
treatment TUG-rate (p<0.05). For Group В no such differ­
ence was detected but taking the two groups together a 
significantly higher mean post-treatment TUG-rate was 
found (0.48 + 26 vs 0.76 ± 0.34 mm) (p<0.05). 
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FIG. 2. The changes in mean (<• -o) and individual (· ·) Three 
week Ulnar Growth rates (TUG-rates) in the six week periods during 
and after a weekly multiple (A) and single dose hCG regimen (B) in 
boys with delayed puberty. The numbers refer to the individual patients. 
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No systematic differences were found in changes in 
body growth rates after stopping hCG injections in either 
group (p > 0 .10) . 
the effect of hCG administration on serum alkaline phos­
phatase activities (fig. 3) 
In figure 3 the changes in the mean and individual 
serum alkaline phosphatase activities (APA) are depicted 
in relation to their respective TUG-rates, showing a 
significant increase in APA during hCG administration in 
Group A from 167 ± 23 to 273 ± 37 U/l (p<0.005) and in 
Group В from 201 ± 32 to 256 ± 52 U/l (p<0.01). 
Comparing the absolute APA, the pretreatment values 
in Group A tended to be lower than in Group B, but the 
difference was not statistically significant (0.10 >p* > 
0.05). During hCG treatment the enzyme levels were almost 
similar in the two groups. Remarkably, the increase in 
ΑΡΑ (Δ APA) in Group A during hCG administration was near­
ly twice as high as in Group Β (ρ*<0.02), whereas the 
TUG-rates did not differ significantly. 
After stopping hCG treatment the decrease of APA was 
only significant taking the two groups together (from 
270 ± 46 to 238+62 U/l, η = 9, ρ<0.05). The mean post-
treatment APA did not differ from the mean pretreatment 
value (206 ± 36 U/l) in these nine boys (p>0.10). 
DISCUSSION 
Human chorionic gonadotropin is widely used as a growth 
promoting agent in boys with short stature and delayed pu­
berty. Doses ranging from 400 to 6000 IU twice or three 
times weekly or even daily during three to six months and 
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FIG. 3. The changes in mean (·-—-») and individual (· ·) Three 
week Ulnar Growth rates (TUG-rates) and the concomitant changes in 
serum alkaline phosphatase activities during six weeks of a weekly 
multiple (A) and single dose HCG regimen (B) in boys with delayed 
puberty. The numbers refer to the individual patients. 
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longer have been recommended (2, 19-22, 31-32). However, 
using the non-invasive ulnar length measuring technique, 
a persistent growth promoting effect could be demonstrated 
even after diagnostic (1500 IU for three days) hCG admi­
nistration (5) . 
The present study, using the same sensitive technique, 
compared the effect of a weekly multiple (3 χ 1500 IU) and 
single dose (1 χ 1500 IU) therapeutic hCG regimen on short 
term growth in boys with delayed puberty. During the two 
protocols gonadotropin administration increased the ulnar 
growth velocity within six weeks from prepubertal values 
to levels similar or even exceeding the physiologically 
occurring pubertal growth spurt (33) . Remarkably, both 
drug regimens proved to be equally potent in increasing 
growth velocity by tripling the basal values. 
The mean body growth rates also increased significant­
ly during hCG administration in the two groups. However, 
in contrast to the changes in individual TUG-rates, which 
far exceeded the limit of confidence, the changes in 
body growth rate were too small in relation to the error 
of measurement (34) to allow evaluation in individual boys. 
After stopping hCG therapy the ulnar growth velocities 
sharply decreased in the two groups to almost identical 
levels during the following six weeks. The post-treatment 
mean ulnar growth velocity was significantly higher than 
the pretreatment value for both groups together, confirming 
data of Reiss using a daily hCG injection regimen for 
longer periods (2). 
In both the single and multiple injection protocol 
changes in serum alkaline phosphatase activities (APA) 
after hCG administration almost parallelled the change in 
ulnar growth rate. However, no correlation was found 
between the two parameters. In both groups APA rose to 
about similar values though the increase was unexpected-
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ly more pronounced in the multiple injection group, des­
pite similar acceleration in growth velocity. After stop­
ping hCG treatment APA slightly fell to pretreatment 
levels. This increase in APA in response to hCG adminis­
tration mimics the physiologically occurring pubertal 
increase which is found to be maximal immediately before 
peak height velocity (35). Gonadotropin induced testos­
terone and/or estrogen secretion in concert with enhanced 
growth hormone release (36-37) may account for the tem­
porarily increased APA during hCG therapy. 
The data presented so far indicate that weekly single 
hCG administration was as effective as the multiple in­
jection therapy in achieving physiological pubertal growth 
velocities in the two groups of boys with delayed puberty 
studied here. This lower dose of hCG might decrease the 
risk of dissociation between skeletal maturation and 
growth enhancement as was already demonstrated for tes­
tosterone therapy, since this phenomenon is apparently 
dose dependent (3, 7). 
The lack of difference in growth promoting effect 
between the two protocols might be explained by the as­
sumption that single as well as multiple weekly gonado­
tropin administration raises circulating androgen levels 
in delayed puberty long enough (14, 17-18) and high 
enough to exceed a critical level which in cooperation 
with growth hormone warrants growth stimulation. Refrac­
toriness of the Leydig cell to subsequent hCG administra­
tion after hCG priming might account for the lack of an 
additional effect on growth velocity after rapidly 
repeated hCG injections (14-16). 
Whatever the precise mechanism may be, the results 
found illustrate that a therapeutic regimen of 1 χ 1500 
IU hCG weekly for six weeks was sufficient to trigger 
the chain of metabolic events leading to pubertal-like 
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growth acceleration in the group studied. 
Scrutinizing the data on growth enhancing effect of 
diagnostic hCG administration (5) one is struck by the 
similarity of the responses in ulnar growth velocities 
and APA patterns in both studies indicating that even 
short lasting Leydig cell stimulation by hCG is suffi­
cient to cause a similar growth acceleration persisting 
for five to six weeks or even longer. In view of the 
Leydig cell refractoriness after hCG priming it might 
even be possible that only one single injection of hCG 
evokes such sustained response. 
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CHAPTER 5 
THE EFFECT OF LOW DOSE ESTROGENS ON SHORT 
TERM GROWTH AND CONCOMITANT BIOCHEMICAL 
PHENOMENA IN GIRLS WITH TALL STATURE 
J.S.G. VAN DEN BOSCH 
A.G.H. SMALS 
P.W.C. KLOPPENBORG 
I.M. VALK 
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SUMMARY 
Using a simple non-invasive ulnar length measuring 
technique a 70 to 80% decrease in ulnar growth velocity 
was found during one interval of nine weeks of low dose 
ethinylestradiol administration (0.050 mg daily) in girls 
with tall stature. This decrease in ulnar growth velocity 
was found to be statistically significant within six and 
even three weeks after starting estrogen loading whereas 
the change in body growth velocity was only significant 
after nine weeks. After stopping estrogen administration, 
ulnar growth velocities increased again but to values 
tending to be lower than before ethinylestradiol loading. 
Serum alkaline phosphatase activities and plasma in-
organic phosphorus and calcium levels also decreased 
significantly during estrogen therapy within nine weeks. 
The results found illustrate that the measuring technique 
used enables evaluation of the short term effect of hor-
monal treatment on growth and thereby related biochemical 
phenomena. 
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INTRODUCTION 
Since the first report on the effect of estrogen admin-
istration on growth in girls with tall stature (1), many 
authors discussed the various aspects of estrogen therapy 
such as the effect on final body height, dose and nature 
of estrogen used, age of initiation and the mechanism of 
action, which is essentially still unknown (2-9). Espe-
cially the last years a revival in this discussion is 
noticeable (10-16). 
The present study deals with another aspect of estro-
gen administration. As published before, the accurate non-
invasive measuring technique developed by Valk enables the 
study of short term growth of the human ulna (17-21). 
Therefore it was thought worthwhile to study the short 
term effect of low dose estrogen administration on growth 
in both ulnar and body length and on the concomitant 
changes in serum alkaline phosphatase activities and plas-
ma calcium and inorganic phosphorus levels in girls with 
constitutionally tall stature. 
MATERIALS AND METHODS 
Thirteen girls with tall stature participated in this 
study. The mean age (± SD) was 13.1 * 1.7 yr (range 11.5 -
17.0 yr), whereas the skeletal age, according to Greulich 
and Pyle (22) was 13.3 ± 1.7 yr (range 11 - 15.5 yr). Mean 
body height amounted to 174.4 ± 6.4 cm (range 161 - 184 cm) 
and was above the 97th percentile for Dutch children (23) 
in eleven girls. Most of the girls were in Tanner stage 
III-IV. Only three had menarche before estrogen was ad-
ministered. After excluding endocrine disorders and 
diagnosing tall stature as constitutional, all girls were 
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given ethinylestradiol (Lynoral , 0.050 mg per day orally) 
during a period of three to six months. 
The growth of the ulnar length was measured using a 
sensitive device developed and described by Valk (17-18) 
and recently summarized by van den Bosch et al. (21). 
Each ulnar length determination comprised six succes-
sive independent measurements. The mean SD of the deter-
minations in this study was 0.20 mm implying an SE of 
0.08 mm. Reliable detection of growth requires a change 
in ulnar length above approximately 0.20 mm. A period of 
three weeks has proved to be long enough to detect growth, 
since normal values for prepubertal and pubertal ulnar 
growth velocity amount to 0,60 and 1.00 mm per three 
weeks respectively. Since the essential of the method is the 
measurement of the change in ulnar growth velocity rather 
than the absolute ulnar length, growth is expressed as the 
Three week Ulnar Growth rate (TUG-rate). 
Body height was measured using a standard device and 
was expressed as the three week body growth rate in cm. 
Growth in ulnar length has been demonstrated to correlate 
highly with growth in body height, the ratio being one to 
five respectively (19). 
Since a period of nine weeks was considered to be suf-
ficient to detect significant changes in both ulnar and 
body length, the mean growth velocity was assessed in all 
girls over one period of nine weeks before and during 
estrogen administration as shown in figure 1. However, in 
order to detect the time interval in which changes became 
first apparent the mean growth velocity was also deter-
mined over an interval of six weeks (n=10) and three 
weeks (n=3) immediately preceding and during the estrogen 
loading (figure 1). 
After three to six months in some of the girls the 
estrogen administration was stopped. This enabled compari-
61 
- Е Е < · • +ЕЕ 
- 6 - 3 0 3 6 9weeks 
FIG. 1. Diagram o u t l i n i n g t h e study period of nine weeks before 
and during e t h i n y l e s t r a d i o l (ЕЕ) a d m i n i s t r a t i o n in t h i r t e e n g i r l s . 
Within t h i s study per iod two i n t e r v a l s were chosen of s i x (n=10 
g i r l s ) and t h r e e weeks (n=3 g i r l s ) r e s p e c t i v e l y in order t o d e t e c t 
in which time i n t e r v a l the e f fect of e s t rogens on growth became 
f i r s t n o t i c e a b l e . 
son of t h e growth v e l o c i t i e s over a t ime i n t e r v a l of n i n e 
and s i x weeks d u r i n g and a f t e r e s t r o g e n a d m i n i s t r a t i o n i n 
a way s i m i l a r t o t h e p r o c e d u r e d e p i c t e d i n f i g u r e 1. No 
s u f f i c i e n t d a t a were a v a i l a b l e over t h e t h r e e week i n t e r ­
v a l s immedia te ly b e f o r e and a f t e r s t o p p i n g . 
I n o r d e r t o a s s e s s t h e c o n c o m i t a n t b i o c h e m i c a l c h a n g e s , 
b l o o d f o r t h e d e t e r m i n a t i o n of plasma c a l c i u m and phospho­
r u s l e v e l s and serum a l k a l i n e p h o s p h a t a s e a c t i v i t i e s was 
sampled b e f o r e and n i n e weeks a f t e r e t h i n y l e s t r a d i o l ad­
m i n i s t r a t i o n . Plasma c a l c i u m and phosphorus l e v e l s were 
d e t e r m i n e d u s i n g r o u t i n e l a b o r a t o r y t e c h n i q u e s . Serum a l ­
k a l i n e p h o s p h a t a s e a c t i v i t i e s were measured u s i n g t h e Bessy 
and Lowry t e c h n i q u e a d a p t e d t o automated a n a l y s i s ( 2 4 ) . 
The mean v a l u e s a r e g iven ± 1 SD. 
STATISTICAL ANALYSIS 
D i f f e r e n c e s i n u l n a r and body growth v e l o c i t i e s d u r i n g 
t h e r e s p e c t i v e p e r i o d s ( b e f o r e - d u r i n g and d u r i n g - a f t e r e s ­
t r o g e n l o a d i n g ) were t e s t e d u s i n g S t u d e n t ' s T - t e s t f o r 
p a i r e d o b s e r v a t i o n s . The growth v e l o c i t i e s b e f o r e and af-
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ter ethinylestradiol administration were compared in the 
same way. 
Differences in plasma calcium and phosphorus levels 
and serum alkaline phosphatase activities before and 
during estrogen loading were also tested using the paired 
Student's T-test. 
RESULTS 
In figure 2 the changes in the mean and individual 
TUG-rates during the nine week interval are depicted. The 
left panel shows the significant decrease of the TUG-rate 
from a pretreatment value of 0.59 ± 0.29 mm to 0.22 + 0.27 
mm during ethinylestradiol loading (p <0.001). The right 
panel refers to the significant increase in TUG-rate from 
0.04 ± 0.17 mm during to 0.22 ± 0.05 mm after stopping 
ethinylestradiol administration (p<0.05). The decrease 
in the mean three week body growth rate from 0.33 + 0.24 
cm before to 0.14 ± 0.26 cm during estrogen administration 
was also statistically significant (p<0.05). No signi-
ficant change in body growth was found after stopping the 
ethinylestradiol loading. 
In figure 3 the changes in the mean and individual 
TUG-rates during both the six and three week intervals 
are similarly depicted. The left panel refers to the 
changes during the six week periods, showing the sta-
tistically significant decrease in TUG-rate from 0.57 ± 
0.27 mm before to 0.13 ± 0.28 mm during ethinylestradiol 
administration (p <0.001). Although there was a tendency, 
the increase in ulnar growth velocity after stopping 
ethinylestradiol treatment lacked statistical signifi-
cance (0.10 >p >0.05). The right panel refers to the sig-
nificant decrease in mean ulnar growth velocity from 
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FIG. 2. The decrease in the mean (· ·) and the individual (· · ) 
TUG-rates during the period of nine weeks of ethinylestradiol (ЕЕ) 
ρ 
a d m i n i s t r a t i o n (Lynoral , 0.050 mg d a i l y ) ( l e f t p a n e l ) . The r i g h t 
panel r e f e r s t o the i n c r e a s e in mean and i n d i v i d u a l TUG-rates 
a f t e r s topping ЕЕ loading in five g i r l s . The numbers i n d i c a t e the 
i n d i v i d u a l g i r l s . 
0,43 + 0.23 mm b e f o r e t o 0 .01 ± 0.24 mm d u r i n g t h r e e 
weeks of e t h i n y l e s t r a d i o l a d m i n i s t r a t i o n ( p < 0 . 0 5 ) and 
t h e o n l y o b s e r v a t i o n of an i n c r e a s e w i t h i n t h r e e weeks 
a f t e r s t o p p i n g . No s i g n i f i c a n t changes i n t h r e e week 
body growth v e l o c i t y c o u l d be d e m o n s t r a t e d d u r i n g e i t h e r 
p e r i o d . 
Comparing t h e mean u l n a r growth v e l o c i t i e s b e f o r e 
s t a r t i n g (0.46 ± 0.20 mm, n=5) and a f t e r s t o p p i n g e s t r o g e n 
l o a d i n g (0.22 ± 0.05 mm, n=5) t h e l a t t e r t e n d e d t o be 
lower (0 .10 > ρ > 0.05) . 
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FIG. 3 . The l e f t panel shows the inc rease in the mean (· ·) and 
the i nd iv idua l (· ·) TUG-rates dur ing s i x weeks of e t h i n y l e s t r a -
d i o l (ЕЕ) t rea tment and the increase a f t e r s topping e t h i n y I s t r a d i c i 
load ing . The r i g h t panel s i m i l a r l y d e p i c t s t h e decreases and i n ­
crease during and a f t e r t h r e e weeks of e t h i n y l e s t r a d i o l adminis­
t r a t i o n . The numbers i n d i c a t e the i n d i v i d u a l g i r l s . 
In f igure 4 the changes in the mean and indiv idual 
TUG-rates are depicted with the concomitant changes in 
serum a l k a l i n e phosphatase a c t i v i t i e s , calcium and inorga­
nic phosphorus l e v e l s . The serum a l k a l i n e phosphatase ac­
t i v i t i e s changed s i g n i f i c a n t l y from 270 ± 160 U/l before 
to 199 ± 133 U/l during e t h i n y l e s t r a d i o l adminis t ra t ion 
( p < 0 . 0 1 , n=ll) . S imi lar ly the plasma calcium and phos­
phorus l eve l s decreased s i g n i f i c a n t l y during therapy 
from respect ive ly 2.41 ± 0.09 t o 2.32 ± 0.05 mmol/l 
( p < 0 . 0 5 , n=10) and from 1.49 ± 0.19 to 1.36 ± 0.20 mmol/l 
(p < 0.05, n=10). 
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FIG. 4. The decrease in the mean (· ·) and the individual (· ·) 
TUG-rates in relation to the concomitant changes in serum alkaline 
phosphatase activities and plasma calcium and inorganic phosphorus 
levels during the nine week period of ethmylestradiol (ЕЕ) treat­
ment. The numbers indicate the individual girls. 
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DISCUSSION 
Using a sensitive measuring device a 70 to 80% decrease 
in TUG-rate was observed even within three weeks of rather 
low dose ethinylestradiol administration in constitutional-
ly tall girls. Using a standard device a significant change 
in body height growth velocity could only be detected after 
nine weeks of estrogen treatment. 
This suppressive effect of estrogens on body height has 
been amply reported in literature (vide supra) but the data 
published cover time intervals of three months or more. 
Wettenhall et al. (9) and Zachmann et al. (8), measuring 
body height with intervals of three to six months, observed 
a deceleration in body height growth velocity during estro-
gen therapy, however with doses considerably higher than 
used in the present study. 
After stopping the estrogen loading the ulnar growth 
velocity increased again within three to nine weeks. This 
is in concordance with the proposed mechanism of action by 
which estrogens decelerate growth velocity by lowering 
plasma somatomedin levels (13). The post-treatment growth 
rates were somewhat lower than in the period immediately 
preceding estrogen administration. This decrease might be 
due to physiological fading of growth capacity with time 
but is more probably the direct consequence of ethinyl-
estradiol therapy with its accelerating effect on the clo-
sure of the epiphyseal disc (8). However, the intended 
study period (of nine weeks) was too short to evaluate 
the effect on skeletal maturation. 
Estrogen treatment induced a - to our knowledge not 
yet reported - significant fall in serum alkaline phospha-
tase activities and phosphorus levels in all girls within 
nine weeks after starting estrogen administration. As 
both parameters reflect bone growth activity (25-27) this 
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decrease is in concordance with the fall in TUG-rate. It 
is unlikely that the steep fall in both serum alkaline 
phosphatase activities and plasma inorganic phosphorus 
levels within the short time interval of nine weeks re­
presents the physiologically occurring fall in these 
serum parameters in boys and girls after achieving peak 
height velocity (27). The admittedly small though statis­
tically significant decrease in calcium levels might also 
be related to the diminished skeletal growth during es­
trogen therapy. Another explanation might be a depressive 
effect of estrogens on cholocalciferol synthesis (28) or 
simply on circulating albumin levels (29). 
The present study illustrates that a non-invasive 
measuring technique as used in this study enables evalu­
ation of the short term effect of hormonal treatment on 
growth and thereby related biochemical phenomena. 
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SUMMARY 
A major problem in androgen treatment of excessive 
height in boys is acceleration of growth velocity es­
pecially in the early stages of therapy. Estrogen treat­
ment in tall girls, in contrast, instantly decelerates 
growth velocity, probably by its plasma somatomedin 
lowering effect. As estrogen administration in male 
subjects causes a similar somatomedin depression and 
immediate growth inhibition is also wanted in the treat­
ment of excessive height in boys, the effect of short 
term low dose estrogen therapy (ethinylestradiol, 
Lynoral , 0.0 50 mg daily) on growth was studied in ten 
constitutionally tall boys. 
During estrogen therapy Three week Ulnar Growth rate 
(TUG-rate) dropped instantly from 0.84 ± 0.42 mm to 0.33 
± 0.27 mm (p<0.02) within six weeks. Three week body 
growth rate also changed significantly from 0.48 ± 0.23 
cm to 0.12 ± 0.37 cm during estrogen loading (p<0.05). 
The magnitude of the latter changes, however, allows 
only evaluation for the whole group, whereas changes in 
TUG-rates far exceeded the limits of confidence in most 
individual boys. 
Growth deceleration during ethinylestradiol (ЕЕ) was 
accompanied by a significant decrease in serum alkaline 
phosphatase activities (from 29 9 ± 72 U/l before to 
240 ± 79 U/l during ЕЕ, ρ<0.01), plasma calcium (from 
2.45 ± 0.06 imnol/1 to 2.35 + 0.05 mmol/1 during ЕЕ, 
ρ <0.05) and plasma testosterone levels (from 392 + 128 
ng/100 ml before to 27 ± 7 ng/100 ml during ЕЕ, ρ<0.005). 
Within two months after stopping ЕЕ administration plasma 
testosterone levels were normal again (432 ± 282 ng/100 
ml) . 
Testicular size was not affected. Mild reversible 
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gynecomastia, however, was present in all boys. 
The results demonstrate an instant growth decelerating 
effect of low dose estrogen administration in tall boys 
reminiscent to the findings in tall girls under the same 
low dose regimen. Furthermore these data provide a theore-
tical base for combining androgens and estrogens in the 
early stages of treatment of excessive height in boys 
in order to antagonize the initial growth accelerating 
effect of androgens alone. 
INTRODUCTION 
In contrast to many reports on estrogen treatment of 
excessively tall girls (for review 1-2) only few papers 
deal with hormonal growth inhibition in tall boys (3-6). 
Like estrogens in tall girls, testosterone treatment in 
tall boys has proven to be successful in reducing final 
body height with regard to predicted height. Major pro-
blem, however, in testosterone therapy is acceleration 
of growth velocity in the early stages after starting 
androgen administration (7-8), particularly in the 
younger bone age group (5). Since serious psychological 
problems are the main indication for sex hormone treat-
ment in most cases, acceleration of growth velocity is 
hardly acceptable when growth inhibition is wanted. 
Estrogen therapy in tall girls, however, decelerates 
growth velocity instantly in most of the patients (9-10) 
even in low doses (11), probably by its somatomedin lo-
wering effect (12-13). This decrease of plasma somatomedin 
by estrogens has also been demonstrated in male subjects 
(14-16). In contrast to estrogens, the effect of andro-
gens on growth velocity is regarded to be independent of 
somatomedin and probably mediated by their anabolic action 
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per se (17-18). These latter actions may temporarily 
increase growth velocity in concert with elevated growth 
hormone levels (19-20) , an undesired effect in the treat­
ment of excessively tall boys. To overcome this initial 
growth accelerating effect of androgens - which occurs 
despite substantial peripheral aromatization of estrogens 
(21-22) - the effect of low dose estrogen therapy on 
short term growth was studied in boys with constitutional 
tall stature, using the sensitive ulnar length measuring 
technique. 
MATERIALS AND METHODS 
Ten constitutionally tall boys volunteered to partici­
pate in this study after obtaining informed parental con­
sent. Data on growth and development at the start of the 
study are tabulated in table 1. Body height was above the 
97th centile for Dutch boys (23) in all patients. 
Ρ 
All boys received 0.050 mg ethinylestradiol (Lynoral ) 
daily over a period varying from six weeks to six months. 
In order to study the short term effect of ethinylestra­
diol growth velocities were assessed over a period of six 
weeks before and six weeks immediately after starting 
therapy. In nine boys the effect of stopping ethinylestra­
diol administration was evaluated measuring growth veloci­
ties six weeks before and after stopping. 
Ulnar growth velocities were measured using the non­
invasive ulnar length measuring technique developed and 
described by Valk (25-26) and recently by van den Bosch 
et al. (27) which enables accurate measurement of short 
term growth (11, 28-30). Each ulnar length determination 
comprised six successive independent measurements by the 
same observer. The mean SD of the samples in this study 
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amounted to 0.20 mm implying a mean SE of 0.0 8 mm. 
Growth in ulnar length was expressed as the Three week 
Ulnar Growth rate in mm, i.e. TUG-rate. 
Growth in body height was determined using the Har-
penden stadiometer and was expressed as the three week 
body growth rate in cm. 
Blood for serum alkaline phosphatase activities, plas-
ma calcium, phosphorus and testosterone levels was sampled 
before, during and after ethinylestradiol administration. 
Serum alkaline phosphatase activities were measured 
using the Bessy and Lowry technique adapted to automated 
analysis (31) . Plasma calcium and phosphorus were deter-
mined using routine laboratory techniques. Plasria testos-
terone was assayed after a paper chromatographic purification 
step using an antiserum generated in rabbits against 11-hydro-
xytestosterone hemisuccinate conjugated to albumin (32). 
Mean values are given ± 1 SD. 
Calendar age 
Bone age* (yr) 
Body height (cm) 
Body weight (kg) 
Testicular size (cm) 
length 
width 
Tanner stage 
Testosterone (ng/100ml) 
MEAN 
14.5 ± 
13.5 ± 
190 ± 
66.3 ± 
4 ± 
3 ± 
404 ± 
t SD 
1.37 
0.9 
6.9 
8.2 
1.1 
0.6 
215 
RANGE 
12.5 -
12.5 -
176.5 -
52.9 -
1.5 -
2 -
II -
13 -
16.0 
15.0 
203.4 
77.0 
5.5 
4 
V 
790 
*According to Greulich and Pyle (24) 
TABLE 1. Characteristics on growth and development in ten con-
stitutionally tall boys at the start of the study. 
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STATISTICAL ANALYSIS 
Differences in ulnar and body growth velocities, serum 
alkaline phosphatase activities, plasma calcium, phospho­
rus and testosterone levels between the respective study 
periods were tested using Student's T-test for paired ob­
servations. The chosen level of statistical significance 
(two sided) was ρ = 0.05. 
RESULTS 
the effect of eth-inylestradiol (ЕЕ) on growth veloa-ity 
(fig. 1) 
The left panel of figure 1 reveals the changes in 
mean and individual TUG-rates during six weeks of ЕЕ ad­
ministration (0.050 mg/daily). The mean TUG-rate de­
creased significantly from 0.84 ± 0.42 mm before to 
0.33 ± 0.27 mm during ЕЕ treatment (p<0.02). In eight 
of the ten boys the decrease in TUG-rate was above the 
limit of confidence (3xSE). 
Three week body growth rate also decreased signifi­
cantly from a mean pretreatment value of 0.48 ± 0.23 cm 
to 0.12 ± 0.37 cm during ЕЕ administration (p<0.05). 
Body weight did not change significantly during ЕЕ loading 
(p > 0.10) . 
the effect of stopping eth-inylestradiol (ЕЕ) administration 
(fig. 1) 
The right panel of figure 1 refers to the changes in 
mean and individual TUG-rates after stopping the ЕЕ loading. 
Mean TUG-rate increased from 0.28 ± 0.32 mm during to 0.53 
77 
± 0.27 mm after stopping ЕЕ. Although there was a tendency 
this difference lacked statistical significance (0.10 >ρ > 
0.05). Ulnar growth velocities before and after ЕЕ adminis­
tration differed neither significantly (p >0.10). 
No changes in body growth rate and body weight were 
found during this part of the study (p >0.10). 
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FIG. 1. The changes in mean (·-—-·) and individual (· ·) Three 
week Ulnar Growth rates (TUG-rates) in ten constitutionally 
tall boys. The left panel refers to the changes in TUG-rates 
ρ 
during six weeks ethinylestradiol (ЕЕ) administration (Lynoral , 
0.050 mg daily, n=10). The right panel reveals the changes in 
TUG-rates during six weeks after stopping ЕЕ in nine of them. 
Individual subjects are indicated by number. 
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the effect of ethinylestradiol (ЕЕ) on bioahenriaal pheno­
mena (fig. 2) 
I n f i g u r e 2 t h e changes i n i n d i v i d u a l and mean serum 
a l k a l i n e p h o s p h a t a s e a c t i v i t i e s , plasma c a l c i u m and p h o s ­
phorus l e v e l s a r e d e p i c t e d in r e l a t i o n t o t h e changes i n 
T U G - r a t e s . The l e f t p a n e l shows t h e changes a f t e r s t o p p i n g 
ЕЕ. 
Serum a l k a l i n e p h o s p h a t a s e a c t i v i t i e s d e c r e a s e d s i g n i ­
f i c a n t l y from a mean l e v e l of 299 ± 72 U/l b e f o r e t o 240 
± 79 U/l d u r i n g ЕЕ l o a d i n g (p < 0 . 0 1 , n = 8 ) . A f t e r s t o p p i n g 
ЕЕ a d m i n i s t r a t i o n t h e mean p h o s p h a t a s e a c t i v i t i e s changed 
from 215 ± 92 U/l t o 240 ± 90 U / l . This i n c r e m e n t was n o t 
s t a t i s t i c a l l y s i g n i f i c a n t ( p > 0 . 1 0 , n = 7 ) . P o s t - t r e a t m e n t 
p h o s p h a t a s e l e v e l s t e n d e d t o be lower t h a n p r e t r e a t m e n t 
a c t i v i t i e s (0.10 >p > 0 . 0 5 ) . 
Mean plasma c a l c i u m d e c r e a s e d d u r i n g ЕЕ l o a d i n g from 
2.45 + 0.06 mmol/1 t o 2.35 ± 0.05 mmol/1 (p < 0 . 0 5 , n=5) . 
A f t e r s t o p p i n g ЕЕ t h e mean plasma c a l c i u m i n c r e a s e d from 
2.36 ± 0.06 t o 2.42 ± 0.07 mmol/1. Although t h e r e was a 
t e n d e n c y t h i s i n c r e m e n t was n o t s t a t i s t i c a l l y s i g n i f i c a n t 
(0.10 >p > 0 . 0 5 , n=5) . 
I n c o n t r a s t t o plasma c a l c i u m and serum a l k a l i n e p h o s ­
p h a t a s e a c t i v i t i e s , t h e r e were no s i g n i f i c a n t changes i n 
plasma phosphorus (1.35 ± 0.18 mmol/1 b e f o r e v e r s u s 1.32 
± 0.23 mmol/l d u r i n g ЕЕ, and 1.34 ± 0.19 mmol/1 d u r i n g 
FIG. 2. The changes in mean (· -·) and i n d i v i d u a l ( ·——·) serum 
a l k a l i n e phosphatase a c t i v i t i e s , plasma calcium and phosphorus 
l e v e l s in r e l a t i o n t o t h e changes in Three week Ulnar Growth r a t e 
(TUG-rate) in c o n s t i t u t i o n a l l y t a l l boys. The l e f t panel r e f e r s 
t o t h e changes dur ing s i x weeks e t h i n y l e s t r a d i o l (ЕЕ) a d m i n i s t r a -
p 
tion (Lynoral , 0.050 mg daily). The right panel illustrates the 
changes during six weeks after stopping ЕЕ. Individual subjects 
are indicated by number. 
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versus 1.30 ± 0.20 mmol/1 after stopping ЕЕ loading, p> 
0.10, n=5). 
During ЕЕ treatment plasma testosterone levels fell 
from a pretreatment value of 392 ± 128 ng/100 ml to 27 
+ 7 ng/100 ml (ρ<0.005, η=5). Within two months after 
stopping ЕЕ loading testosterone levels had increased 
again to normal values (432 ± 282 ng/100 ml, ρ <0.05, 
n=5). Two of these five boys were treated for six weeks, 
two for four months and one for six months. 
the effect of ethinylestradiol (ЕЕ) on teetioular size 
and mammary gland 
In none of the ten boys testicular size was markedly 
reduced during ЕЕ therapy. The only change observed was 
a slight weakening of the testis in the boys treated 
for four to six months. 
The effect on mammary gland tissue was more overt. 
Eight boys developed moderate gynecomastia within six 
weeks of ЕЕ administration, two boys only after longer 
treatment. Gynecomastia remained within acceptable limits 
for the patients and disappeared after stopping ЕЕ treat­
ment within two months. 
DISCUSSION 
This study for the first time demonstrates the instant 
growth inhibiting effect of low dose estrogens in tall boys. 
The significant decrease of ulnar growth rate in response 
to this low dose of ethinylestradiol (ЕЕ) was almost iden­
tical to that found in tall girls (11). In both groups of 
tall girls and boys studied, body growth rate also decrea­
sed significantly during estrogen therapy. However, the 
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magnitude of the changes in body height allows only evalu­
ation for the whole group, whereas the changes in TUG-rates 
far exceeded the limit of statistical confidence (3xSE) 
in nearly all individual youngsters. 
After stopping ЕЕ administration ulnar growth rates 
tended to increase again, a phenomenon also observed in 
tall girls. Both the decelerating effect during ЕЕ and the 
acceleration after stopping ЕЕ might be in accordance with 
the proposed mechanism of action of estrogens on plasma 
somatomedin levels, which is well documented in literature 
for both sexes (12-16). A second mechanism accounting for 
the growth inhibition in these boys might be direct or 
indirect estrogen mediated suppression of Leydig cell 
function (33-36) illustrated by the overt fall of plasma 
testosterone levels to prepubertal values during treat­
ment. Finally both mechanisms may simultaneously contri­
bute to growth inhibition in boys. Mere growth hormone 
suppression as the cause of the instant growth inhibition 
can be ruled out since estrogens have been reported to 
even increase circulating HGH levels, probably due to the 
positive feedback of somatomedin reduction (15, 37). 
This study on short term growth clearly demonstrates 
that also in tall boys low doses of estrogen are effective 
in instantly reducing growth velocity. Very recently the 
growth inhibiting effect of low dose estrogens was confir­
med in a long term study in tall girls (38). 
The decrease in growth rate during ЕЕ was also reflec­
ted by a significant reduction of serum alkaline phospha­
tase activities and plasma calcium levels, similar to that 
found in girls (11). In contrast to this latter study the 
plasma phosphorus levels did not change significantly in 
the boys, probably due to the smaller number of data 
available. The reduction of serum alkaline phosphatase 
activities during ЕЕ is opposite to the rise observed during 
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human chorionic gonadotropin (hCG) induced growth stimu­
lation (27, 30) and therefore probably reflects diminished 
bone growth (39). The small but significant decrease in 
plasma calcium levels during ЕЕ might be explained by a 
depressive effect of estrogens on cholicalciferol syn­
thesis (40) or on circulating albumin (41) , but is more 
likely related to diminished skeletal growth during ЕЕ. 
Testicular size was not affected during ЕЕ administra­
tion in this study and Leydig cell function was only tem­
porarily suppressed as illustrated by the rapid recovery 
of plasma testosterone levels after stopping ЕЕ. An essen­
tial issue to be discussed is the hazard of potential 
infertility due to estrogen treatment in men. As in testos­
terone treatment (5, 10) estrogens cause oligo-azoöspermia 
(42-46) but under both drug regimens infertility has been 
reported to be reversible in animals (43-44) and men (5, 
10, 42, 45-46) using even much higher doses of estrogens. 
Although gynecomastia was manifest, it was mild and 
reversible in all boys. 
Together these data illustrate that low dose estrogen 
therapy in boys results in instant growth deceleration 
which to our opinion is an important psychological ad-
vantage in the early management of tall stature in boys. 
Moreover the findings provide a theoretical base for 
temporarily combining androgens and estrogens in the 
early stages of treatment in tall boys in order to anta-
gonize the initial growth accelerating effect of andro-
gens alone. 
REFERENCES 
1. WETTENHALL Η Ν В, CAHILL С, and ROCHE A F (1975) : Tall 
girls. J Pediatr 86: 602. 
83 
NEW M I, LEVINE L S, YAFFE S J, SOYKA L F, GURPIDE E, 
SEGAL S J and van WIJK J J (1973) : Report on the 
conference on estrogen treatment of the young. 
Pediatrics 62: 1087 (Suppl). 
WHITELAW M J, FOSTER Th W and GRAHAM W H (1965) : 
Steroidal induction of the premature growth spurt 
in pubertal boys for excessive height. Acta Endocri-
nologica (Kbh) 50: 317. 
RUVALCABA R H A , TATTONI D S and KELLY V C (1975) : 
Androgen therapy in an "excessively" tall boy. Am 
J Dis Child 129: 95. 
ZACHMANN M, FERRANDEZ A, MURSET G, GNEHM H E and PRADER 
A (1976): Testosterone treatment of excessively 
tall boys. J Pediatr 88: 116. 
BIERICH J R (1979): Hochwuchs. Mschr Kinderheilk 127: 
551. 
BIERICH J R and SCHÖNBERG D (1975) : Hormonal treatment' 
of familial tall stature. Acta Paediatr Scand 62: 
90. 
MARSHALL W A (1977): Human growth and its disorders. 
Academic Press, London, ρ 166. 
ZACHMANN M, FERRANDEZ A, MURSET G and PRADER A (1975): 
Estrogen treatment of excessively tall girls. Helv 
Paediatr Acta 3 0: 11. 
PRADER A, and ZACHMANN M (1978) : Treatment of excessi­
vely tall girls and boys with sex hormones. Pedia­
tric 62: 1202. 
van den BOSCH J S G, SMALS A G H, KLOPPENBORG Ρ W С and 
VALK Ι M (1981): The effect of low dose estrogens 
on short term growth and concomitant biochemical 
phenomena in girls with tall stature. Acta Endocri-
nologica (Kbh) 98:156 
84 
12. von PUTTKAMMER К, BIERICH J R and SCKONBERG D (1975): 
Efficiency and mode of action of conjugated oes-
trogens in the treatment of tall girls. Pediatr 
Res 9: 685. 
13. von PUTTKAMMER H, BIERICH J R, BRUGGER F, HIRCHE W and 
SCHÖNBERG D (1977): Ostrogentherapie bei Mädchen 
mit konstitutionellem Hochwuchs. Dtsch Med Wschr 
102: 983. 
14. WIEDEMANN E and SCHWARTZ E (1972): Suppression of growth 
hormone-dependent human serum sulfation factor by 
estrogen. J Clin Endocrinol Metab 34: 51. 
15. WIEDEMANN E, SCHWARTZ E and FRANTZ A G (1976): Acute 
and chronic estrogen effects upon serum somato-
medin activity, growth hormone and prolactin in 
man. J Clin Endocrinol Metab 42: 942. 
16. CLEMMONS D R, UNDERWOOD L E, RIDGWAY E С, KLIMAN В 
KJELLBERG R N and van WIJK J J (19 80): Estradiol 
treatment of acromegaly. Am J Med 69: 571. 
17. van den BRANDE J L and CAJU M С V (1974) in: Raiti 
S (ed) Advances in human growth hormone research. 
DHEW pubi, no. NIH 74-612 US Govt printing office, 
Washington DC, ρ 98. 
18. PHILIPS L S and VASSILOPOULOU-SELLIN R (19 80): Soma­
tomedins. N Engl J Med 30 2: 4 38. 
19. MARTIN L G, CLARK J W and CONNOR Th В (1968): Growth 
hormone secretion enhanced by androgens. J Clin 
Endocrinol Metab 28: 425. 
20. AYNSLEE-GREEN A, ZACHMANN M and PRADER A (1976) : 
Interrelation of the therapeutic effects of growth 
hormone and testosterone on growth in hypopituita­
rism. J Pediatr 89: 992. 
21. SANTEN R J (1975): Is aromatization of testosterone to 
estradiol required for inhibition of luteinizing 
hormone secretion in men? J Clin Invest 56: 1555. 
85 
22. MATSUMOTO A, PAULSEN С A, BREMNER W J (1981): In man, 
human chorionic gonadotropin stimulates normal 
testosterone production and spermatogenesis in 
spite of very high estradiol levels. Clin Res 29: 
84A (Abstract). 
23. van WIERINGEN J C, WAFELBAKKER F, VERBRUGGE H Ρ, and 
de HAAS (1968): Groeidiagrairanen Nederland 1965 
Wolters-Noordhoff, Groningen. 
24. GREULICH W W and PYLE S E (1970): Radiographic Atlas 
of skeletal development of the hand and the wrist. 
Stanford University Press, Stanford. 
25. VALK Ι M (1971): Accurate measurement of the length 
of the ulna and its application in growth measure­
ment. Growth 35: 297. 
26. VALK I M (1972): Ulnar length and growth in twins with 
a simplified technique for ulnar measurement using 
a condylograph. Growth 36: 291. 
27. van den BOSCH J S G, SMALS A G H, KLOPPENBORG Ρ W С and 
VALK I M (1979): Short term growth in boys with de­
layed puberty after diagnostic human chorionic go­
nadotropin administration. J Clin Endocrinol Metab 
49: 387. 
28. VALK Ι M (1974) : Ulnar growth in boys around the age of 
puberty. Growth 38: 437. 
29. VALK I M and van den BOSCH J S G (1978): Intradaily 
variation of the human ulnar length and short term 
growth - a longitudinal study in eleven boys. 
Growth 42: 107. 
30. van den BOSCH J S G, SMALS A G H, VALK Ι M and KLOPPEN­
BORG Ρ W С (1981): Lack of difference in growth sti­
mulating effect between weekly single and multiple 
human chorionic gonadotropin administration in boys 
with delayed puberty, Clin Endocrinol, in press. 
86 
31. BESSY О A, LOWRY А О and BROCK M J (1946): A method for 
the rapid determination of alkaline phosphatase 
with five cubic millimeters of serum. J Biol Chem 
164: 321. 
32. SMALS A G H, KLOPPENBORG Ρ W С, LEQUIN R M and BENRAAD 
Th J (1976) : The effect of gonadotrophin releasing 
hormone on pituitary-gonadal function in Kline-
felters's syndrome. Acta Endocrinol (Kbh) 83: 829. 
33. YANAIHARA T, TROEN P, TROEN В R and TROEN M L (1972): 
Studies on the human testis III Effect of oestrogen 
on testosterone formation in human testis in vitro. 
J Clin Endocrinol Metab 34: 968. 
34. SMALS A G H, KLOPPENBORG Ρ W С, LEQUIN R M and BENRAAD 
Th J (1974) : The effect of estrogen administration 
on plasma testosterone, FSH and LH levels in 
patients with Klinefelter's syndrome and normal men. 
Acta Endocrinologica (Kbh) 77: 7 65. 
35. JONES Th M, FANG V S, LANDAU RL and ROSENFIELD R (1978): 
Direct inhibition of Leydig cell function by estra­
diol. J Clin Metab 47: 1368. 
36. SMALS A G H, DRAYER J I M , BOERS G, BENRAAD Th J and 
KLOPPENBORG Ρ W С (19 80) : Indirect evidence of 
transient estrogen mediated 17.20 lyase suppres­
sion in hCG treated men. Clin Res 28: 627A (Ab­
stract) . 
37. BIERICH J R (1978): Estrogen treatment of girls with 
constitutional tall stature. Pediatrics 62: 1196. 
38. van der WERFF ten BOSCH J J and ВОТ A (19 81): Growth 
in tall girls without and during oestrogen treat­
ment. Neth J Med 24: 52. 
39. ROUND J M, BUTCHER S and STEELE R (1979): Changes in 
plasma inorganic phosphorus and alkaline phospha­
tase activity during the adolescent growth spurt. 
Ann Hum Biol 6: 129. 
87 
BAKSI S N and KENNY A D (1978): Regulation of vitamin 
D metabolism by gonadal hormones and dietary cal­
cium in adult Japanese quail. Proceedings of the 
sixth Parathyroid Conference, Vancouver, Canada, 
Exerpta Medica, Amsterdam, Oxford, ρ 370. 
KAMYAB S, BAGHDIANTZ A and MOTAMEDI Η (1978): Varia­
tions in serum protein fractions following a con­
tinuous long term intake of eugynon and lyndiol 
by Iranian women. J Steroid Biochem 8: 811. 
HELLER С G, LAIDLAW W M, HARVEY Η Τ, NELSON W О 
(1958): Effects of progestational compounds on 
the reproductive processes of the human male. Ann 
NY Acad Sci 71: 649. 
KALRA S Ρ and PRASAD M R N (1969) : Recovery of sperma-
togenic and androgenic activity in adult male rats 
following long-term treatment with estrogen. Fértil 
Steril 20: 495. 
NEUMANN F, von BERSWORDT-WALLRABE R, ELGER W, STEINBECK 
H, HAHN J D and KRAMER M (1970): Aspects of androgen 
dependent events as studied by anti-androgens. In: 
Astwood Ε В (ed). Recent progress in hormone re­
search. Proceedings of the 1969 Laurentian hormone 
conference. Academic Press, New York-London, ρ 394. 
BRIGGS M and BRIGSS M (1974) : Oral contraceptive for 
men. Nature 252: 585. 
SCHOYSMAN R (1976) : Present state of male contraception. 
In: Hubinot Ρ О, L'Hermite M (eds). Sperm action-
progress in reproductive biology. S Karger, Basel, 
ρ 295. 

SUMMARY 
SAMENVATTING 
90 
SUMMARY 
This thesis describes the results of the application 
of a non-invasive ulnar length measuring technique in 
short term growth studies in tall and short statured ado-
lescents treated with sex hormones. 
The technique used enables accurate determination of 
growth in ulnar length over short time periods, mostly 
three weeks. Ulnar growth velocity is therefore expressed 
as the Three week Ulnar Growth rate (TUG-rate). Earlier 
it was demonstrated that growth in ulnar length highly 
correlates with growth in body height (r = 0.83), the 
ratio being one to five. However, the time period neces-
sary for reliable detection of growth in body height is, 
despite higher velocity, three times longer. Moreover 
the method of the ulnar length measuring technique allows 
statistical evaluation for each individual TUG-rate found. 
In previous studies the average prepubertal and pubertal 
TUG-rates in girls and boys with normal body length 
appeared to be 0.6 mm and 1.0 mm respectively. Given a 
mean limit of confidence as low as 0.20 mm this ulnar 
length measuring technique enables reliable detection of 
changes in growth velocities over short periods. Therefore 
this technique was applied in response studies in children 
treated for excessive tall and short stature, aged between 
11 and 17 yrs. None of these adolescents had apparent 
endocrine disorders, in fact all showed a variant of 
normal growth. The group studied was divided into two 
categories: i boys with serious delay in growth and 
sexual development. Body height was below the 10th 
centile for Dutch children, ii Boys and girls with 
excessively tall stature, exceeding the 97th centile. 
Before the response to treatment could be studied 
in these patients, the problem of transient changes 
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in ulnar length during the day had to be solved, since 
such changes might influence the evaluation of short 
term growth. 
Chapter two deals with this problem. During a period 
of three weeks the ulnar length of eleven boys was 
measured at seven set times between 08.00 h and 18.00 h. 
An overt diurnal rhythm was observed. Between 08.00 h 
and 12.00 h ulnar length decreased significantly for an 
average of 0.4 mm. During the afternoon no further 
significant changes in ulnar length could be detected. 
Despite this diurnal decrease a mean overall pubertal 
TUG-rate of 1.0 mm could be calculated. These findings 
suggested that growth in ulnar length occurs mainly 
during the night. Since changes in ulnar length during 
the morning are most pronounced patients should be 
measured in the afternoon and preferably at the same 
time in order to minimalize the influence of intra-
daily variation of ulnar length on short term growth. 
In chapter three short term growth was studied in 
ten boys with delayed puberty receiving human chorionic 
gonadotropin (hCG) for diagnostic purposes. This low 
dose of hCG increased ulnar growth velocity from low 
prepubertal to pubertal values for approximately 6 weeks. 
This growth promoting effect was preceded by an overt 
rise in plasma testosterone and associated with an almost 
doubling of serum alkaline phosphatase activities. These 
changes temporarily mimicked the physiologically occur-
ring phenomena inherent to the initiation of the growth 
spurt. 
In view of these results and the reported relative 
refractoriness of the Leydig cell to repeated hCG admin-
stration for 48 hours or longer after the priming dose, 
two therapeutic hCG regimens were compared. Chapter four 
reports on this study in which one group of boys with 
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delayed puberty received the usually recommended weekly 
multiple injection protocol (3 χ 1500 IlJ/weekly), the 
other a weekly single dose of hCG (1 χ 1500 IU), both 
during six weeks. The two hCG regimens appeared to be 
equally potent in stimulating TUG-rates, tripling the 
ulnar growth velocities from prepubertal to pubertal 
levels. After stopping hCG administration the mean TUG-
rates again decreased but to a level significantly higher 
than before treatment. In contrast to the former study 
(chapter three) mean body growth rate increased signi­
ficantly during hCG administration. However, the extent 
of the changes only allowed evaluation of the whole 
group, whereas changes in TUG-rates far exceeded the 
limit of confidence in all but one boy. 
In this study serum alkaline phosphatase activities 
also increased during hCG treatment concomitant with 
the increase in TUG-rates. The results indicate that a 
weekly single dose of hCG was sufficient and as effec­
tive as the usually recommended weekly multiple dose 
protocol to stimulate TUG-rates to pubertal values. 
In chapter five short term growth was studied in a 
group of excessively tall girls receiving a low dose of 
ethinylestradiol (0.05 mg daily). Using the ulnar length 
measuring technique it appeared that this low dose of 
estrogen decreased growth velocity significantly within 
six and even three weeks. Only after nine weeks the 
decrease in body growth rate became statistically sig­
nificant. After stopping estrogen administration TUG-
rates increased again. 
Besides serum alkaline phosphatase activities, plasma 
calcium and phosphorus levels also changed significantly, 
decreasing during ethinylestradiol administration. The 
data found illustrate that even low doses of estrogens, 
as used in oral contraceptives, may decelerate growth 
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velocity and do so instantly. 
Chapter six also deals with low dose estrogen the-
rapy but - as was not yet reported before - in excessi-
vely tall boys. As for girls instant growth inhibition 
in tall boys is wanted and often needed. The usually 
reconunended androgen therapy, however, accelerates 
growth in the early stages of therapy. In view of the 
data found in tall girls and reported theories on the 
mode of action of estrogens, ten boys with excessively 
tall stature were given a low dose of estrogen to study 
the effect on short term growth. TUG-rates decreased 
significantly and instantly and the changes found were 
almost identical to those observed in tall girls. Body 
growth rate significantly decreased too, but only for 
the whole group. After stopping estrogen treatment TUG-
rates increased again in accordance with the proposed 
mechanism of action. As was expected alkaline phospha-
tase activities and serum calcium levels decreased 
significantly during ethinylestradiol administration, 
only the changes in phosphate levels lacked statistical 
significance. No serious or irreversible side effects 
were observed during this study. The results found il-
lustrate that low doses of estrogens instantly dece-
lerate growth velocity in tall boys which may be an 
important advantage in the early management of exces-
sively tall stature. 
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SAMENVATTING 
In dit proefschrift worden de resultaten beschreven 
van de toepassing van een niet-invasieve ulnalengtemeter 
voor de bestudering van groei op de korte termijn van te 
lange en te kleine adolescenten, die behandeld worden met 
geslachtshormonen. 
De gebruikte techniek maakt een nauwkeurige bepaling 
van de toeneming in ulnalengte mogelijk binnen korte tijd, 
meestal drie weken. De verandering in ulnalengte wordt 
dan ook uitgedrukt als driewekelijkse groeisnelheid, de 
zgn. TUG-rate (Three week Ulnar Growth rate). Reeds eer-
der werd een nauwe relatie aangetoond tussen de toeneming 
in ulnalengte en de toeneming van de totale lichaamslengte, 
welke laatste ongeveer vijf maal zo hoog is als de groei-
snelheid van de ulna. Ondanks deze hogere snelheid is het 
tijdsinterval, waarbinnen op betrouwbare wijze groei kan 
worden gemeten drie keer zo lang als bij de gebruikte tech-
niek voor het meten van de ulna. Bovendien maakt deze wijze 
van meten het mogelijk iedere TUG-rate te toetsen aan een 
betrouwbaarheidsgraad. In voorgaande studies werd bij 
jongens en meisjes met een normale lichaamslengte een ge-
middelde prepuberale en puberale toeneming van de ulna-
lengte gevonden van respectievelijk 0.6 mm en 1.0 mm per 
drie weken. Bij een gemiddelde betrouwbaarheidsgraad van 
0.2 mm maakt dit een nauwkeurige meting van veranderingen 
in groeisnelheid binnen korte tijd mogelijk..De techniek 
werd daarom geschikt geacht om het effect van therapie te 
bestuderen bij te kleine en te lange adolescenten. Geen van 
deze kinderen had een endocrinologische afwijking en er 
kon bij allen gesproken worden van een variant van normale 
groei. De groep te kleine kinderen bestond uit jongens met 
een achterstand in groei en ontwikkeling. De lichaamslengte 
in deze groep was lager dan de 10e percentiel zoals die in 
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1965 voor normale Nederlandse kinderen werd gevonden 
door van Wieringen en medewerkers. De groep zeer lange 
adolescenten bestond uit jongens en meisjes, wier 
lichaamslengte de 97e percentiel overschreed. 
Voordat echter het effect van therapie op de groei 
van deze kinderen kon worden bestudeerd diende het ver-
schijnsel van de veranderingen in ulnalengte gedurende 
de dag nader te worden onderzocht. 
Daarvoor werd gedurende een periode van drie weken tel-
kens op zeven vaste tijdstippen tussen acht uur 's 
morgens en zes uur 's avonds de ulnalengte gemeten bij 
elf jongens. In hoofdstuk twee worden de resultaten van 
deze studie beschreven. Een duidelijk dagritme kon wor-
den aangetoond. Tussen acht en twaalf nam de ulnalengte 
met 0.4 mm gemiddeld significant af. Gedurende de mid-
dag werden geen significante veranderingen gevonden. 
Opmerkelijk is, dat deze vermindering van de ulnalengte 
gedurende de dag optrad ondanks een gemiddelde puberale 
groeisnelheid van 1.0 mm per drie weken. Dit suggereert, 
dat groei van de ulna voornamelijk gedurende de avond 
en/of nacht plaats vindt. 
Gezien de snelle daling van de ulnalengte 's morgens en 
de relatief stabiele lengte 's middags verdient het aan-
beveling de patiënten 's middags te meten bij voorkeur 
op dezelfde tijd om eventueel storende invloeden van dit 
dagritme op de groeimetingen te minimaliseren. 
In hoofdstuk drie wordt de korte-termijn-groei van 
jongens met een vertraagde puberteit beschreven, die om 
diagnostische redenen humaan choriogonadotrofine (hCG) 
kregen toegediend. Deze kortdurende toediening van hCG 
leidde tot een duidelijke toeneming van de plasmatestos-
teronspiegels en een significante versnelling van de 
groei van de ulna van laag prepuberale tot puberale 
waarden. Daarnaast trad er een verdubbeling van de alka-
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lische fosfatase-activiteit in het bloed op. Tesamen 
weerspiegelen deze veranderingen de gebeurtenissen 
welke normaliter bij het begin van de groeispurt kunnen 
worden waargenomen. 
Gezien deze bevindingen en de recente publicaties, 
wijzend op een relatief verminderde gevoeligheid van de 
Leydig cel voor snel herhaalde hCG injecties, werd het 
van belang geacht het effect van twee door ons gebruikte 
therapeutische hCG doseringen op de korte-termijn-groei 
te vergelijken. Hoofdstuk vier beschrijft deze studie, 
waarin ëên groep jongens met een vertraagde puberteits-
ontwikkeling de algemeen aanbevolen dosering van drie 
hCG injecties per week kreeg; een andere, vergelijkbare 
groep kreeg slechts één injectie hCG per week, beide 
gedurende zes weken. De twee doseringen bleken gelijke-
lijk in staat de groei te versnellen van laag prepuberale 
naar puberale waarden. Na het stoppen van de hCG toe-
diening daalde de groeisnelheid weer, hoewel deze op 
een significant hoger niveau bleef dan voor de behande-
ling. 
In tegenstelling tot de vorige studie veranderde de 
groeisnelheid van de lichaamslengte in dit onderzoek wel 
significant gedurende de hCG toediening. De toeneming 
was echter van dien aard, dat deze alleen voor de hele 
groep significant was, terwijl de veranderingen in TUG-
rates de betrouwbaarheidsgrens ver overschreden bij alle 
jongens op een na. 
Ook in deze studie nam de alkalische fosfatase-activiteit 
in het bloed significant toe gedurende de therapie, waar-
bij de stijging praktisch gelijke tred hield met de toe-
neming in TUG-rates. 
De resultaten tonen aan dat een dosering van ëên injec-
tie hCG per week even effectief blijkt als de gewoonlijk 
aanbevolen dosering van drie injecties per week om een 
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puberale groeisnelheid te bewerkstellingen. 
In hoofdstuk vijf wordt een groep meisjes beschreven, 
die een lage dosis oestrogenen ontvingen als behandeling 
van hun overmatige groei. Er werd een significante daling 
van de groeisnelheid van de ulna waargenomen binnen zes 
en zelfs binnen drie weken na het begin van de toediening 
van oestrogenen. De afname van de groei in lichaamslengte 
werd echter pas na negen weken statistisch significant. 
Na het stoppen van de oestrogenen medicatie nam de gemid­
delde TUG-rate weer toe, maar bleef onder het niveau van 
de snelheid ббг therapie . 
Tegelijk met de afnemende groeisnelheid namen ook de 
alkalische fosfatase-activiteit, de calcium- en fosfor-
spiegels in het bloed gedurende het toedienen van oestro­
genen significant af. 
Deze bevindingen laten zien dat ook een lage dosis oestro­
genen, zoals gebruikt in orale contraceptiva, een groei-
remmend effect heeft, welk effect onmiddellijk na start 
van de toediening optreedt. 
In hoofdstuk zes wordt eveneens het effect van een 
lage dosis oestrogenen op de groei beschreven, maar nu -
hetgeen nog niet eerder werd gedaan - bij bovenmatig 
lange jongens. Evenals bij meisjes is ook bij deze jon­
gens vaak een onmiddellijke groeiremming gewenst. De 
gebruikelijke therapie met androgenen is in dit opzicht 
dan ook paradoxaal daar deze aanvankelijk de groei 
stimuleert. 
Gezien de resultaten van het onderzoek bij meisjes en 
de publicaties betreffende het werkingsmechanisme van 
oestrogenen werden tien te lange jongens behandeld met 
een lage dosis ethinyloestradiol. Binnen zes weken trad 
een significante daling van de groeisnelheid van de 
ulna op, identiek aan die gevonden bij meisjes. Welis­
waar nam ook de groei in lichaamslengte af, maar deze 
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afname was alleen statistisch significant voor de hele 
groep. Na staken van de toediening van oestrogenen nam 
de groeisnelheid weer toe, overeenkomstig het beschre-
ven werkingsmechanisme. 
Evenals bij meisjes daalden ook bij deze jongens de al-
kalische fosfatase-activiteit en het plasmacalcium sta-
tistisch significant. Dit gold niet voor de daling van 
het fosfaatgehalte. 
Tijdens en na de toediening van deze lage dosis oestro-
genen werden geen ernstige of blijvende bijwerkingen 
gezien. 
De resultaten tonen aan, dat een directe groeiremming 
verkregen wordt met behulp van oestrogenen bij te lange 
jongens, hetgeen een belangrijk psychologisch voordeel 
kan zijn bij het begin van de behandeling. 
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STELLINGEN 
I 
De techniek en methode van ulnalengtemeting zoals ontwikkeld 
door Valk maakt het mogelijk op zeer korte termijn het effect 
van hormonale therapie bij individuele patiënten met groei-
stoornissen te meten. 
Dit proefschrift. 
II 
Het gevonden dagritme in de ulnalengte bij gelijktijdig optre-
dende groei suggereert, dat deze groei 's nachts plaats vindt. 
Dit proefschrift. 
III 
Bij het voorschrijven van de "combinatiepil" aan jonge meisjes 
dient rekening te worden gehouden met het groeiremmende effect 
van lage doses oestrogenen. 
Dit proefschrift. 
J.J. v.d. Werff ten Bosch & A. Bot (1981), 
Ned J Med 24, 52. 
IV 
Het a lka l i sche fosfatase in het serum van gezonde opgroeiende 
kinderen i s een goede maat voor de g r o e i a c t i v i t e i t . 
Dit p r o e f s c h r i f t . 
Round e t a l . (1979), Ann Hum Biol 6, 129. 
V 
Het onderzoek naar de groeiversnelling na ziekte - met name na 
koorts - werd reeds in 1877 door Bowditch aanbevolen. 
H.P. Bowditch (1Θ77) Growth of Children, 
Boston. 
VI 
Om de invloed van het seizoen op de lengtegroei van kinderen 
te verklaren dient o.a. de invloed van meteorologische fac-
toren op dit groeiproces te worden bestudeerd. 
VII 
Het feit, dat de moderne geneeskunde zeer doeltreffend is bij 
de behandeling van specifieke symptomen, wil nog niet zeggen, 
dat ze de gezondheid van de patiënt beter is gaan dienen. 
Ivan Illich (197Θ) Grenzen aan de Genees­
kunde . 
VIII 
De zogenaamde kleine co-schappen KNO, dermatologie en oogheel­
kunde dienen zeker voor a.s. huisartsen drastisch te worden 
uitgebreid, waarbij het zelf werken een grotere plaats zou 
moeten innemen. 
IX 
Het anatomie-onderwijs op de medische faculteit zou met behoud 
van vorm en inhoud d.m.v. accentverschuivingen meer afgestemd 
moeten worden op de kliniek. Daarvoor is een intensiever con­
tact tussen anatomen en klinici noodzakelijk. 
X 
Een groot a a n t a l jonge hui sar t sen zal vanwege de hoge schulden­
l a s t noodgedwongen nieuwe ontwikkelingen in de e e r s t e l i j n s zorg 
tegenhouden. 
S t e l l i n g e n behorende b i j h e t p r o e f s c h r i f t van J . S . G . van den Bosch "Short 
term growth in t a l l and s h o r t s t a t u r e d adolescents t r e a t e d with sex hor­
mones", Nijmegen, 27 november 1981. 


